LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
Key Highlights
- ➤LB-102 preclinical data show increased dopamine neurotransmission via D2 autoreceptor modulation
- ➤NOVA-1 analysis found dose-dependent, statistically significant cognitive improvements primarily direct
- ➤NOVA-2 Phase 3 schizophrenia trial and NOVA-3 extension remain ongoing
- ➤ILLUMINATE-1 Phase 2 bipolar depression trial evaluates cognition, anhedonia, and treatment-emergent mania
Expert Statements
Susan G. Kozauer, Chief Medical Officer of LB Pharmaceuticals
“Our continued progress in the late-stage development of LB-102 for schizophrenia and mood disorders is reflected in the breadth of our presentations at ECNP this year”
Susan G. Kozauer, Chief Medical Officer of LB Pharmaceuticals
“We are encouraged by the new preclinical data that provide further insights into the emerging clinical and tolerability profile of LB-102.”
Susan G. Kozauer, Chief Medical Officer of LB Pharmaceuticals
“These data strengthen the scientific rationale for the development of LB-102 in mood disorders and highlight a potential mechanism for addressing symptoms such as anhedonia that are common across several neuropsychiatric disorders.”
NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the presentation of four posters at the 39(th) European College of Neuropsychopharmacology (ECNP) Congress, taking place in Munich, Germany from October 10-13, 2026. The posters highlight new preclinical data describing LB-102’s differentiated mechanism of action, the pivotal program of LB-102 in schizophrenia (NOVA-2 and NOVA-3), the ongoing late-stage development of LB-102 in bipolar depression (ILLUMINATE-1), and a previously reported analysis of LB-102’s impact on cognitive performance from the Phase 2 NOVA-1 trial in schizophrenia.
“Our continued progress in the late-stage development of LB-102 for schizophrenia and mood disorders is reflected in the breadth of our presentations at ECNP this year,” said Susan G. Kozauer, LB Pharmaceutical’s Chief Medical Officer. “We are encouraged by the new preclinical data that provide further insights into the emerging clinical and tolerability profile of LB-102. These data strengthen the scientific rationale for the development of LB-102 in mood disorders and highlight a potential mechanism for addressing symptoms such as anhedonia that are common across several neuropsychiatric disorders.”
Get started
Create a free account to read the full story.